Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced it was notified by the New York Stock Exchange (the “NYSE”) that the Company is in compliance with the NYSE continued listing requirement pertaining to market capitalization and stockholders’ equity, as modified by the NYSE. This continued listing criterion, as modified, requires a company to maintain shareholders’ equity of at least $50 million if the company’s average market capitalization over a 30-day trading period is less than $50 million. Previously, the numeric thresholds in this requirement were $75 million. This modification is effective through October 31, 2009. The NYSE has stated that it anticipates a subsequent rule filing prior to October 31, 2009 to make this change a permanent continued listing standard. As of April 5, 2009, the completion of the Company’s most recent quarterly period, its stockholders’ equity totaled $74.9 million. As previously announced, Theragenics was notified by the NYSE on March 18, 2009 that it had fallen below compliance with the continued listing standards, as the Company’s stockholders’ equity, shareholders’ equity and market capitalization over 30 trading days was below $75 million.
Theragenics Corporation(NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle-based products. Theragenics’ surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics’ brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer. For additional information, call Theragenics’ Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.
Contacts:
Theragenics Corporation
Frank Tarallo, 800-998-8479 or 770-271-0233
CFO
and Treasurer
or
Lisa Rassel, 800-998-8479 or 770-271-0233
Manager
of Investor Relations
RASSELL@THERAGENICS.COM
WWW.THERAGENICS.COM